RxDoctor Payments Data

Brett Sharp, MD

Child & Adolescent Psychiatry · Logan, UTNPI 1750301529

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 285 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 12.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,420, more than ten times the $90 reported in 2021. Among child & adolescent psychiatry clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,220in general payments, 2019–2025

Across 285 payments — averaging $18.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$625
  • Teva Pharmaceuticals USA, Inc.$622
  • Johnson & Johnson$594
  • Neurocrine Biosciences, Inc.$510
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$405
  • Takeda Pharmaceuticals U.S.A., Inc.$382
  • plus $2K from 20 others

What the payments were for

  • Food & beverage$5,220100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,220 in reported general payments places this provider in the 95th percentile of 29 child & adolescent psychiatry providers in Utah.

See all child & adolescent psychiatry providers in Utah

Medicare billing

Part B allowed, 2024
$15,815
Medicare patients
21
Services billed
170

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SpravatoEsketamine Hcl27$53,368
Lurasidone Hcl56$4,769
Asenapine Maleate13$2,142
Vilazodone Hcl12$1,346
Bupropion XlBupropion Hcl31$683
Trazodone Hcl32$614
Prazosin Hcl18$544
Lamotrigine34$528
Sertraline Hcl18$176
Clonazepam29$171
Quetiapine Fumarate13$169
Duloxetine Hcl13$167
Gabapentin22$159
Metformin Hcl ErMetformin Hcl12$111
Escitalopram Oxalate26$96

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato$594$53,36827 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 29 child & adolescent psychiatry providers in Utah.

Other child & adolescent psychiatry in Logan

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →